Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPA and Dexamethasone for CINV Prevention in Breast Cancer
NCT03862144Phase 2Completed
- Sponsor
- Consorzio Oncotech
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of netupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Consorzio Oncotech. Primary endpoint: Complete response. Started May 2016; status: completed.
02
Drugs
netupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03862144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862144.